Leading Global Battery Expert Kenneth Hoffman to Join Pure Lithium as Special Advisor
21.4.2025 16:52:00 CEST | Business Wire | Press release
Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announces that Kenneth Hoffman (CFA, CIM) will join the company as a Special Advisor, leveraging his vast experience across the battery value chain to advance our drive towards full commercialization.
Mr. Hoffman, who was previously Global Head of Battery Materials at McKinsey, will be a crucial asset for Pure Lithium’s commercialization strategy and development of partnerships. Working directly with Pure Lithium CEO Emilie Bodoin, he will bring a deep understanding of batteries and a unique ability to connect market dynamics with operational decision making that will be invaluable for Pure Lithium.
Pure Lithium Founder and CEO Emilie Bodoin said:
“I feel very privileged to bring Ken aboard at this crucial time in Pure Lithium’s evolution. He is simply one of the leading experts on batteries, forming partnerships and developing successful businesses in energy storage. We are sure that he going to make a major contribution to Pure Lithium as we move toward commercial production of our next-generation lithium metal vanadium battery.”
Mr. Hoffman has spent more than 25 years in investing, managing and directing tens of billions of dollars as a Portfolio Manager, and global Director of Research for various large funds including Millennium Partners and Reservoir Capital. His broad, hands-on experience as an investor and consultant will help Pure Lithium identify and capitalize on business and financial opportunities and bring vast insight to mitigating supply chain risks.
In late 2016, Mr. Hoffman agreed to join McKinsey’s Global Energy & Mining practice (GEM) to lead mining company strategy in gold, copper, nickel, manganese and lithium as well as battery raw material value chains. He has worked on more than 100 due diligences from the analysis of lithium assets to the study of more than a dozen direct lithium extraction technologies.
He is one of the main presenters at metal and mining forums as well as global battery conferences and global media, including an opening keynote at PDAC, The Future Minerals Forum in Riyadh, Fastmarkets events in Asia, North America, Europe and South America, the London Metals Exchange Week conferences in Hong Kong and London and Australia’s AUSIMM general gathering. Mr. Hoffman is a Director of “The Battery Show,” the largest battery event in North America.
About Pure Lithium
Pure Lithium is a disruptive Boston-based lithium metal battery technology company led by its founders, inventor and lithium expert, CEO Emilie Bodoin, and world-renowned battery and metallurgical expert, MIT Emeritus Professor Donald R. Sadoway, as full-time CSO. The Company's novel Brine to Battery™ technology combines metal extraction and anode production, bypassing traditional lithium compound production. The resulting pure lithium metal anode is the core component of our lithium metal vanadium oxide battery, a step-change improvement over today’s lithium-ion technology in cell performance, cost and safety. Additionally, the battery is free of graphite, cobalt, nickel and manganese. For more information, visit www.purelithium.io or email news@purelithium.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421673825/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom